EcoDrugPlus

Solute Carrier Family 18 Member A2

Ensembl ID : ENSG00000165646
Gene: SLC18A2
Gene Synonyms: SVAT,SVMT,VMAT2
13 APIs:
10 Enzyme and pathways 8 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 22 Member 11

Ensembl ID : ENSG00000168065
Gene: SLC22A11
Gene Synonyms: OAT4
1 APIs:
5 Enzyme and pathways 7 Cross references
891 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 22 Member 12

Ensembl ID : ENSG00000197891
Gene: SLC22A12
Gene Synonyms: OAT4L,RST,URAT1
7 APIs:
9 Enzyme and pathways 8 Cross references
475 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 22 Member 6

Ensembl ID : ENSG00000197901
Gene: SLC22A6
Gene Synonyms: OAT1,PAHT,ROAT1
2 APIs:
5 Enzyme and pathways 7 Cross references
495 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 22 Member 8

Ensembl ID : ENSG00000149452
Gene: SLC22A8
Gene Synonyms: OAT3
2 APIs:
7 Enzyme and pathways 7 Cross references
304 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSG00000112759
Gene: SLC29A1
Gene Synonyms: ENT1
1 APIs:
7 Enzyme and pathways 8 Cross references
280 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 5 Member 1

Ensembl ID : ENSG00000100170
Gene: SLC5A1
Gene Synonyms: D22S675,NAGT,SGLT-1,SGLT1
2 APIs:
10 Enzyme and pathways 8 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 5 Member 2

Ensembl ID : ENSG00000140675
Gene: SLC5A2
Gene Synonyms: SGLT2
14 APIs:
7 Enzyme and pathways 8 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 1

Ensembl ID : ENSG00000157103
Gene: SLC6A1
Gene Synonyms: GABATHG,GABATR,GAT-1,GAT1,HGAT-1
1 APIs:
9 Enzyme and pathways 8 Cross references
279 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 2

Ensembl ID : ENSG00000103546
Gene: SLC6A2
Gene Synonyms: NAT1,NET,NET1,SLC6A5
63 APIs:
8 Enzyme and pathways 8 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 3

Ensembl ID : ENSG00000142319
Gene: SLC6A3
Gene Synonyms: DAT,DAT1
21 APIs:
13 Enzyme and pathways 8 Cross references
167 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Solute Carrier Family 6 Member 4

Ensembl ID : ENSG00000108576
Gene: SLC6A4
Gene Synonyms: 5-HTT,HTT,OCD1,SERT1
34 APIs:
4 Enzyme and pathways 8 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).